greeksoup/ stock research
Stock research / United States / ABT · Pharmaceutical Preparations · NYSE

Abbott Laboratories (ABT)

Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. On 19 November 2025 it entered into a definitive agreement to acquire Exact Sciences Corporation, which the filing says is expected to let Abbott enter the cancer diagnostics market; the acquisition is subject to customary closing conditions including approval by Exact Sciences shareholders and regulatory clearances.

Abbott Laboratories

Abbott Laboratories is an Illinois corporation, incorporated in 1900, whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. On 19 November 2025 it entered into a definitive agreement to acquire Exact Sciences Corporation, which the filing says is expected to let Abbott enter the cancer diagnostics market; the acquisition is subject to customary closing conditions including approval by Exact Sciences shareholders and regulatory clearances.

Established Pharmaceutical Products

Branded generic pharmaceuticals, made worldwide but marketed and sold outside the United States, in emerging markets. They go directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies and independent retailers from Abbott-owned distribution centres or public warehouses, and some products are co-marketed, co-promoted with, or licensed from other companies. The therapeutic portfolios include gastroenterology, with Creon for pancreatic exocrine insufficiency, Duspatal and Dicetel for irritable bowel syndrome or biliary spasm, Heptral, Transmetil and Samyr for intrahepatic cholestasis or depressive symptoms and Duphalac for regulating the rhythm of the colon, and women's health, with Duphaston for gynecological disorders and Femoston, a hormone replacement therapy for postmenopausal women.

Diagnostic Products

Diagnostic systems and tests sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, alternate care testing sites and plasma protein therapeutic companies. Core laboratory and transfusion medicine covers immunoassay, clinical chemistry, hematology and transfusion serology, on the Alinity family of instruments and the ARCHITECT and Cell-Dyn systems, used to screen for or diagnose cancer, cardiac and metabolic disorders, drugs of abuse, thyroid function, fertility, neurologic and general chemistries, infectious disease and therapeutic drug monitoring. Molecular diagnostics runs polymerase chain reaction systems, Alinity m and m2000, which automate extraction, purification and preparation of DNA and RNA from patient samples, plus the Vysis genomic test line for oncology. Point-of-care testing is the i-STAT and i-STAT Alinity systems and their cartridges. Rapid diagnostics covers lateral flow tests including BinaxNOW and Panbio, molecular point-of-care systems including ID NOW and m-PIMA, cardiometabolic tests on Afinion and Cholestech LDX, and a toxicology business for drug and alcohol testing. Around all of it sit informatics and automation products: the GLP systems Track laboratory automation, the AlinIQ informatics suite, the Indexor system for pre-analytics sample traceability and the RALS point-of-care solution.

Nutritional Products

Pediatric and adult nutrition made, marketed and sold worldwide, direct to consumers and to institutions, wholesalers, retailers, healthcare facilities, government agencies and third-party distributors. Infant and follow-on formula runs under the Similac name in many variants, plus EleCare, Gain and Grow. Adult and other pediatric nutrition includes Ensure and its variants, Glucerna, ProSure, PediaSure, Juven, Abound and Pedialyte. A third group is used for enteral feeding in healthcare institutions: Jevity, Osmolite, Oxepa, Nepro, Vital and the Freego enteral pump and sets. Marketing is aimed at consumers and at physicians and other healthcare professionals, with direct consumer marketing where it is permitted.

Medical Devices

Cardiovascular devices, diabetes care and neuromodulation, made, marketed and sold worldwide, in the United States generally direct to wholesalers, hospitals, ambulatory surgery centres, physicians' offices, consumers and distributors, and elsewhere either directly or through distributors.

Rhythm management covers the Assurity MRI and Endurity MRI pacemakers, the Aveir single-chamber and dual-chamber leadless pacemakers, implantable cardioverter defibrillators including Gallant and Fortify Assura, and implantable cardiac monitors including Confirm Rx and Jot Dx. Electrophysiology covers the Volt pulsed field ablation system, the TactiFlex and TactiCath ablation catheter families, the EnSite cardiac mapping systems and the ViewFlex intracardiac echocardiography catheters. Heart failure covers the HeartMate left ventricular assist device family, the CardioMEMS pulmonary artery sensor and the CentriMag acute mechanical circulatory support system.

Vascular covers the XIENCE drug-eluting coronary stents, the Perclose and StarClose vessel closure devices, TREK coronary balloon dilatation, the Supera peripheral stent, carotid stent systems, the OPTIS imaging systems with their Dragonfly catheters and PressureWire fractional flow reserve measurement, the Diamondback 360 orbital atherectomy systems and the Esprit resorbable scaffold. Structural heart covers MitraClip and TriClip, the transcatheter edge-to-edge repair systems for the mitral and tricuspid valves, the Epic surgical valve family, Navitor transcatheter aortic valves, mechanical heart valves and the Amplatzer occluders. Diabetes care is the FreeStyle and Libre continuous and blood glucose monitoring systems, including the FreeStyle Libre system with its sensors, software, test strips and accessories, and the Lingo system aimed at health and wellness rather than diabetes.

From Abbott's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Abbott Laboratories became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 4 November 2026
Revenue
$13.0 billion
+14.5% on the year · +3.3% on the quarter
Q4 FY2024Q3 FY2026
Net income
$920 million
-44.0% on the year · -0.9% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$0.53
-43.6% on the year · 0.0% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 20 February 2026
Revenue
$44.3 billion
+5.7% on the year
FY2018FY2025
Net income
$6.5 billion
-51.3% on the year
FY2018FY2025
Diluted EPS
$3.72
-51.3% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsAbbott Laboratories (ABT) reported revenue of $44.3 billion for fiscal 2025, the year ended 31 December 2025, up 5.7% on the year before. Net income was $6.5 billion and diluted earnings per share $3.72. Revenue was $42.0 billion in fiscal 2024, $40.1 billion in fiscal 2023, $43.7 billion in fiscal 2022 and $43.1 billion in fiscal 2021. Net income in the same years was $13.4 billion, $5.7 billion, $6.9 billion and $7.1 billion. Over the twelve months to 30 September 2026, Abbott Laboratories reported revenue of $48.2 billion and net income of $4.7 billion. Revenue grew 5.1% a year, compounded, over the five years to fiscal 2025. Abbott Laboratories declared $2.52 a share in dividends over the last four quarters and had 1.73 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $31.2 billion of debt and $4.1 billion of cash. At the close of 6 November 2026 the market cap of Abbott Laboratories was $190.5 billion, 41.0 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE9.2%
ROCE8.1%
Operating margin13.8%
Net margin9.7%
FCF margin14.0%
Interest cover6.7x
Debt to equity0.61x
Cash conversion1.88x
Share count, last 12 months-0.4%
Sales CAGR, 3 years0.5%
Profit CAGR, 3 years-2.0%
EPS, TTM$2.68

At the close of 6 November 2026

Price$109.97
Market cap$190.5 billion
Stock P/E41.0x
Price to book3.7x
EV / EBITDA20.6x
Dividend yield2.3%
Market cap / sales4.0x
52-week high$130.59
52-week low$82.56
Price, 1 year-12.0%
Price CAGR, 3 years5.1%
Price CAGR, 5 years-2.4%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Abbott Laboratories files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
ABTgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue11,46811,89511,25710,41010,0919,7479,97810,14310,2419,96410,37710,63510,97410,35811,14211,36911,45911,16412,59313,013
Cost of revenue4,7664,9874,9334,6294,5934,3314,4834,6054,5564,4634,6034,6984,9424,4684,8545,0754,9224,8905,3255,628
Gross profit6,7026,9086,3245,7815,4985,4165,4955,5385,6855,5015,7745,9376,0325,8906,2886,2946,5376,2747,2687,385
Gross margin58%58%56%56%54%56%55%55%56%55%56%56%55%57%56%55%57%56%58%57%
R&D762697684782725654715672700684698713749716725766735767892920
SG&A3,0482,7872,7572,7312,9732,7622,7402,7232,7242,9592,9362,8952,9073,0613,0913,0513,1293,7404,0254,266
Operating income2,3782,9122,3761,7701,3041,5091,5421,6471,7801,3861,6691,8591,9111,6932,0522,0572,2511,3451,6931,358
Operating margin21%24%21%17%13%15%15%16%17%14%16%17%17%16%18%18%20%12%13%10%
Interest expense131131132141154153159166159141140142136131121121120174351350
Pre-tax income2,3272,8762,3521,7581,3201,5621,6361,6711,7951,4361,6071,9402,0301,7782,1502,1802,3581,4491,5241,231
Tax rate15%15%14%18%22%16%16%14%11%15%19%15%-355%25%17%25%25%26%39%25%
Net income1,9892,4472,0181,4351,0331,3181,3751,4361,5941,2251,3021,6469,2291,3251,7791,6441,7761,077928920
Net margin17%21%18%14%10%14%14%14%16%12%13%15%84%13%16%14%15%10%7%7%
Diluted EPS$1.11$1.37$1.14$0.81$0.59$0.75$0.78$0.82$0.91$0.70$0.74$0.94$5.27$0.76$1.01$0.94$1.01$0.61$0.53$0.53
Operating cash flow3,0672,0652,4102,7802,3261,1431,2031,8773,0381,0251,9602,7052,8681,4172,0472,7873,3151,3152,4881,737
Capital expenditure614321379467610380507560755398533556720484502496689399497513
Free cash flow2,4531,7442,0312,3131,7167636961,3172,2836271,4272,1492,1489331,5452,2912,6269161,9911,224
Buybacks9742,3075.07986855404262.02592263.07513152806.03053021801,04511.0
Dividends paid7988328288268238908908888889579619609581,0261,0291,0311,0301,0981,1021,094
Shares outstanding1,763m1,751m1,751m1,744m1,738m1,739m1,735m1,736m1,735m1,740m1,740m1,734m1,734m1,740m1,740m1,739m1,738m1,742m1,730m1,732m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017 †FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue25,91429,52830,76535,16721,40719,05019,65720,24720,40520,85327,39030,57831,90434,60843,07543,65340,10941,95044,32848,229
Cost of revenue11,42212,61213,20914,66510,0178,8999,1939,2188,7479,09412,40912,70613,23115,00318,53719,14217,97518,70619,31920,765
Gross profit14,49216,91617,55520,50211,39010,15110,46411,02911,65811,75914,98117,87218,67319,60524,53824,51122,13423,24425,00927,464
Gross margin55.9%57.3%57.1%58.3%53.2%53.3%53.2%54.5%57.1%56.4%54.7%58.4%58.5%56.6%57.0%56.1%55.2%55.4%56.4%56.9%
Research and development2,5062,6892,7443,7241,5121,4611,3711,3451,4051,4472,2602,3002,4402,4202,7422,8882,7412,8442,9423,314
Selling, general and administrative7,4088,4368,40610,3767,3656,7356,3726,5306,7856,7369,1829,7449,7659,69611,32411,24810,94911,69712,33215,160
Operating income4,5795,6946,2366,0881,6291,3602,1332,5992,8673,0261,5643,6504,5325,3578,4258,3626,4786,8258,0536,647
Operating margin17.7%19.3%20.3%17.3%7.6%7.1%10.9%12.8%14.1%14.5%5.7%11.9%14.2%15.5%19.6%19.2%16.2%16.3%18.2%13.8%
Interest expense593528520553359320145150163431904826670546533558637559493995
Pre-tax incomen/an/a7,1945,7131,236-2202,0412,5183,1831,4132,2312,8734,0774,9688,2118,3066,6647,0138,4666,562
Income tax8631,1221,4481,087110-45753.07975773501,8785393904971,1401,373941-6,3891,9421,861
Effective tax raten/an/a20.1%19.0%8.9%n/a2.6%31.7%18.1%24.8%84.2%18.8%9.6%10.0%13.9%16.5%14.1%-91.1%22.9%28.4%
Net income3,6064,8815,7464,6264,7285,9632,5762,2844,4231,4004772,3683,6874,4957,0716,9335,72313,4026,5244,701
Net margin13.9%16.5%18.7%13.2%22.1%31.3%13.1%11.3%21.7%6.7%1.7%7.7%11.6%13.0%16.4%15.9%14.3%31.9%14.7%9.7%
Diluted EPS$2.31$3.12$3.69$2.96$3.01$3.72$1.62$1.49$2.92$0.94$0.27$1.33$2.06$2.50$3.94$3.91$3.26$7.64$3.72$2.68
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Medical Devicesn/an/an/an/an/an/an/an/a10,32511,37012,23911,78714,48514,80216,88718,98621,38748.3%
Diagnostics3,5783,7944,1264,2924,5454,7214,6464,8135,6167,4957,71310,80515,52616,4699,9889,3418,93720.2%
Nutritionals5,2845,5325,9896,4616,7406,9536,9756,8996,9257,2297,4097,6478,2947,4598,1548,4138,45119.1%
Established Pharmaceuticals2,9414,4615,3552,7692,8623,1183,7203,8594,2874,4224,4864,3034,7184,9125,0665,1945,53612.5%
Cardiovascular and Neuromodulation Productsn/an/an/an/an/an/a2,7922,896n/an/an/an/an/an/an/an/an/an/a
Othern/an/a2,6042,4572,4982,4692,2722,3862376257n/an/an/an/an/an/an/a
Proprietary Pharmaceutical Products13,54515,389n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Vascular Products2,6923,1943,3333,0713,0122,986n/an/an/an/an/an/an/an/an/an/an/an/a
Unallocated amount2,7252,797n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Medical Devices FY2017 to FY2025DiagnosticsNutritionalsEstablished PharmaceuticalsOther FY2011 to FY2019Cardiovascular and Neuromodulation Products FY2015 to FY2016Vascular Products FY2009 to FY2014Proprietary Pharmaceutical Products FY2009 to FY2010
32.4FY201019.7FY201320.9FY201631.9FY201943.6FY202244.3FY2025

$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Unallocated amount is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Profit by segment FY2020 to FY2025

The operating profit each segment reports. Costs Abbott Laboratories does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2020FY2021FY2022FY2023FY2024FY2025Margin
FY2025
Medical Devices3,0384,5334,4365,3066,1537,21233.7%
Diagnostics3,7256,2376,6402,4332,0731,74019.5%
Nutritionals1,7511,7637061,3331,5051,55818.4%
Established Pharmaceuticals7948891,0491,2061,2331,29023.3%
Medical DevicesDiagnosticsNutritionalsEstablished Pharmaceuticals
9.3FY202013.4FY202112.8FY202210.3FY202311.0FY202411.8FY2025

$ billion; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Medical Devices48%61%
Diagnostics20%15%
Nutritionals19%13%
Established Pharmaceuticals12%11%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by region FY2010 to FY2025

FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States15,1946,3026,2426,2086,1236,2706,4869,67310,83911,39813,02216,64218,14215,45216,32317,12638.6%
All Other Countries8,2504,9714,2244,6625,3244,5497,9619,94311,21511,93612,82315,72615,01014,16814,78615,97936.0%
Germany1,8461,0588379639781,0041,0441,3661,6191,7512,1082,5722,3402,3452,5392,7596.2%
Chinan/a6258591,0831,3211,7961,7282,1462,3112,3461,9652,3922,1332,2532,1131,9074.3%
India501n/a9199221,0091,0531,1141,2371,3331,3971,3231,5611,6491,7501,8171,8714.2%
Switzerlandn/a5916937927077847668411,0051,0681,1401,3131,3361,6381,7471,8714.2%
Japan2,025n/a1,2211,0429688959241,2551,3261,4351,3861,6951,9321,5131,4411,4753.3%
United Kingdom8884,751396395447430n/an/an/an/an/an/an/a9911,1851,3403.0%
Braziln/a470448470508381n/an/an/an/an/an/an/an/an/an/an/a
COn/an/an/a205283388n/an/an/an/an/an/an/an/an/an/an/a
Canada1,036652471493462428n/an/an/a573841n/an/an/an/an/an/a
France1,216781453480n/a375n/an/an/an/an/an/an/an/an/an/an/a
Italy1,144761412457436383n/an/an/an/an/an/an/an/an/an/an/a
Netherlands2,001n/a1,107960788855830929930n/an/a1,1741,111n/an/an/an/a
RUn/an/a485525536483n/an/an/an/an/an/an/an/an/an/an/a
Spain1,066447283n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
VNn/an/an/an/a357331n/an/an/an/an/an/an/an/an/an/an/a
United StatesAll Other CountriesGermanyChina FY2011 to FY2025India FY2010 to FY2025Switzerland FY2011 to FY2025Japan FY2010 to FY2025Other
21.4FY201119.7FY201320.4FY201527.4FY201731.9FY201943.1FY202140.1FY202344.3FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Abbott Laboratories's adjusted EPS landed at or above the top of the range in 0 and inside it in 3 of the 3 years shown (FY2018 to FY2024).

−0.7%FY2018−1.3%FY2023−0.6%FY2024
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2018$2.80 to $2.90$2.88
FY2023$4.30 to $4.50$4.44
FY2024$4.50 to $4.70$4.67
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017 †FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow5,1846,9957,2758,7368,9709,3143,3243,6752,9663,2035,5706,3006,1367,90110,5339,5817,2618,5589,5668,855
Capital expenditure1,6561,2881,0891,0151,4921,7951,1451,0771,1101,1211,1351,3941,6382,1771,8851,7772,2022,2072,1712,098
Free cash flow3,5285,7076,1867,7217,4787,5192,1792,5981,8562,0824,4354,9064,4985,7248,6487,8045,0596,3517,3956,757
Free cash flow margin13.6%19.3%20.1%22.0%34.9%39.5%11.1%12.8%9.1%10.0%16.2%16.0%14.1%16.5%20.1%17.9%12.6%15.1%16.7%14.0%
Cash from investingn/a-2,087-3,699-12,188661-5,560-3,929-202406-248-9,618-1,356-1,815-2,215-2,008-1,740-3,133-2,338-2,422-22,295
Cash from financingn/a-3,4861,002-1,088-6,423195-6,696-2,742-2,23611,147-5,281-10,391-4,289-2,779-5,494-7,636-7,091-5,404-6,3099,993
Depreciation and amortisation1,8551,8392,0902,6243,0442,7831,7191,5481,4721,3533,0213,2783,0143,3273,5383,2673,2433,2183,1163,911
Share-based compensation430347366387383433262246292310406477519546640685644673664735
Buybacks1,0591,08282686777.02,3641,6052,1952,2375221172387184032,2993,7951,2271,2958931,538
Dividends paid1,9592,1742,4142,6712,9383,1838821,3421,4431,5391,8491,9742,2702,5603,2023,3093,5563,8364,1164,324
Dividend per sharen/an/a$1.60$1.76$1.92n/an/an/an/an/an/an/an/an/an/a$1.92$2.08$2.24$2.40n/a
Diluted shares, weighted1,560m1,561m1,555m1,556m1,567m1,592m1,574m1,527m1,506m1,483m1,749m1,770m1,781m1,786m1,789m1,764m1,749m1,748m1,748m1,738m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a1,732m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012 †FY2013 †FY2014 †FY2015FY2016 †FY2017 †FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity17,77917,48023,14422,67724,44026,72125,17121,52621,21120,53830,89730,52431,08832,78435,80236,68638,60347,66452,13051,027
Non-controlling interest45.439.143.188.386.392.096.0113115179201198213219222219224237641596
Short-term borrowings1,8271,6914,978n/an/an/an/an/an/an/an/an/an/an/a0.0n/an/an/an/an/a
Debt10,3869,75411,47718,91815,41520,4766,5617,8309,00122,00627,92419,56618,13918,74718,05016,77314,67914,12512,92931,159
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a755902956943949896931n/a
Other liabilities9,67613,45512,93918,89020,33619,94611,12511,80610,9209,94317,22816,88517,69219,89620,16619,81718,75918,49220,08225,465
Total liabilities and equity39,71442,41952,58260,57460,27767,23542,95341,27541,24752,66676,25067,17367,88772,54875,19674,43873,21481,41486,713108,247
Owned
Fixed assets7,5187,2197,6197,9717,8748,0635,9055,9355,7305,7057,6077,5638,0389,0298,9599,16210,15410,65811,81612,880
Goodwill10,1299,98713,20015,93015,70515,7749,77210,0679,6387,68324,02023,25423,19523,74423,23122,79923,67923,10824,03532,643
Intangible assets5,7205,1516,29212,1529,9908,5885,7356,1985,5624,53921,47318,94217,02514,78412,73910,4548,8156,6475,52619,591
Investments1,4902,0412,2562,1051,6634,6454,7426265,1653,1021,0861,1391,1631,1311,2661,0541,1821,2371,3351,345
Cash and equivalents2,4564,1128,8093,6486,81310,8023,4754,0635,00118,6209,4073,8443,8606,8389,7999,8826,8967,6168,5224,052
Receivables4,9475,4666,5427,1847,6847,6133,9863,5863,4183,2485,2495,1825,4256,4146,4876,2186,5656,9257,9299,032
Inventory2,9512,7763,2653,1893,2843,7922,6932,6432,5992,4343,6013,7964,3165,0125,1576,1736,5706,1946,4887,337
Other assets4,5025,6674,5988,3957,2647,9576,6458,1574,1347,3353,8073,4534,8655,5967,5588,6969,35319,02921,06221,367
Total assets39,71442,41952,58260,57460,27767,23542,95341,27541,24752,66676,25067,17367,88772,54875,19674,43873,21481,41486,713108,247
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded8.1%5.1%0.5%10.0%
Profit growth, compounded4.0%7.7%-2.0%-66.4%
Return on equity, average13.6%18.8%18.5%12.5%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Abbott Laboratories' revenue in fiscal 2025?

Abbott Laboratories (ABT) reported revenue of $44.3 billion for fiscal 2025, the year ended 31 December 2025, up 5.7% on the year before.

How much did Abbott Laboratories earn in fiscal 2025?

Net income was $6.5 billion for fiscal 2025, and diluted earnings per share $3.72.

What is Abbott Laboratories' P/E ratio?

At the close of 6 November 2026, Abbott Laboratories traded at 41.0 times its earnings over the twelve months to 30 September 2026.

What is Abbott Laboratories' market cap?

The market cap of Abbott Laboratories was $190.5 billion at the close of 6 November 2026.

Does Abbott Laboratories pay a dividend?

Yes. Abbott Laboratories declared $2.52 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on ABT

Dividends$2.52 a share over the four quarters to 30 September 2026, a 2.29% yield
Filings27 in twelve months: 15 current reports (8-K), about 5 other events; 4 results of operations; 3 charter or bylaw amendment, or fiscal year change; 3 material agreement; 2 regulation FD disclosure
Planned insider sales13 Form 144 notices in twelve months, $51.3 million; latest 5 November 2026
Options tapeput/call 0.51 by open interest at the 6 November 2026 close; the straddle prices a 3.2% move to 13 November 2026
13F holders2,997 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading12 sales and 6 purchases on Form 4 in twelve months
Congress13 House trades disclosed in six months
Short interest17.4 million shares short, 1.78 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20264 November 2026EDGAR
10-Q30 June 202628 July 2026EDGAR
10-Q31 March 202629 April 2026EDGAR
10-K31 December 202520 February 2026EDGAR
10-Q30 September 202529 October 2025EDGAR
10-Q30 June 202530 July 2025EDGAR
10-Q31 March 202530 April 2025EDGAR
10-K31 December 202421 February 2025EDGAR
10-Q30 September 202431 October 2024EDGAR
10-Q30 June 202431 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.